Compare CANG & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANG | IMMP |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.4M | 58.2M |
| IPO Year | 2018 | 2012 |
| Metric | CANG | IMMP |
|---|---|---|
| Price | $0.45 | $0.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 05-13-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $428.72 | $417.85 |
| Revenue Next Year | $18.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.29 |
| 52 Week High | $5.75 | $3.53 |
| Indicator | CANG | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 14.38 |
| Support Level | $0.33 | N/A |
| Resistance Level | $0.50 | $0.39 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 70.65 | 21.27 |
Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.